Neuropace, Inc. NPCE Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Neuropace, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s return on equity?
- Neuropace, Inc. (NPCE) reported return on equity of -111.4% in Q1 2026.
- How has Neuropace, Inc.'s return on equity changed year-over-year?
- Neuropace, Inc.'s return on equity increased by 13.3% year-over-year, from -128.5% to -111.4%.
- What is the long-term trend for Neuropace, Inc.'s return on equity?
- Over 3 years (2022 to 2025), Neuropace, Inc.'s return on equity has grown at a 22.2% compound annual growth rate (CAGR), from -87% to -158.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.